206 related articles for article (PubMed ID: 9408961)
1. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
Valkov NI; Sullivan DM
Semin Hematol; 1997 Oct; 34(4 Suppl 5):48-62. PubMed ID: 9408961
[TBL] [Abstract][Full Text] [Related]
2. The use of topoisomerase I inhibitors in multiple myeloma.
Kraut EH; Ju R; Muller M
Semin Hematol; 1998 Jul; 35(3 Suppl 4):32-8. PubMed ID: 9779880
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
Bridewell DJ; Finlay GJ; Baguley BC
Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
[TBL] [Abstract][Full Text] [Related]
4. Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
Holden JA
Ann Clin Lab Sci; 1997; 27(6):402-12. PubMed ID: 9433537
[TBL] [Abstract][Full Text] [Related]
5. DNA topoisomerase II as a potential factor in drug resistance of human malignancies.
Potmesil M; Hsiang YH; Liu LF; Wu HY; Traganos F; Bank B; Silber R
NCI Monogr; 1987; (4):105-9. PubMed ID: 3041236
[TBL] [Abstract][Full Text] [Related]
6. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
7. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
[TBL] [Abstract][Full Text] [Related]
8. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.
Adjei AA; Charron M; Rowinsky EK; Svingen PA; Miller J; Reid JM; Sebolt-Leopold J; Ames MM; Kaufmann SH
Clin Cancer Res; 1998 Mar; 4(3):683-91. PubMed ID: 9533538
[TBL] [Abstract][Full Text] [Related]
9. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
10. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne.
Gatto B; Sanders MM; Yu C; Wu HY; Makhey D; LaVoie EJ; Liu LF
Cancer Res; 1996 Jun; 56(12):2795-800. PubMed ID: 8665516
[TBL] [Abstract][Full Text] [Related]
11. Etoposide-induced DNA strand breaks in relation to p-glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL.
Zhou R; Vitols S; Gruber A; Liliemark J; Wang Y; Liliemark E
Br J Haematol; 1999 May; 105(2):420-7. PubMed ID: 10233413
[TBL] [Abstract][Full Text] [Related]
12. Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line.
Pu QQ; Bezwoda WR
Anticancer Res; 2000; 20(4):2569-78. PubMed ID: 10953328
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance.
Wilson CS; Medeiros LJ; Lai R; Butch AW; McCourty A; Kelly K; Brynes RK
Mod Pathol; 2001 Sep; 14(9):886-91. PubMed ID: 11557785
[TBL] [Abstract][Full Text] [Related]
14. The measurement of nuclear topoisomerase II inhibition in vitro: a possible tool for detecting resistance on a subcellular level in haematopoietic malignancies.
Boege F; Gieseler F; Biersack H; Meyer P
Eur J Clin Chem Clin Biochem; 1992 Feb; 30(2):63-8. PubMed ID: 1316175
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
[TBL] [Abstract][Full Text] [Related]
16. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
López-Lázaro M; Willmore E; Jobson A; Gilroy KL; Curtis H; Padget K; Austin CA
J Nat Prod; 2007 Dec; 70(12):1884-8. PubMed ID: 18076140
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
Parajuli P; Yano S; Nishioka Y; Nokihara H; Hanibuchi M; Nishimura N; Utsugi T; Sone S
Oncol Res; 1999; 11(5):219-24. PubMed ID: 10608616
[TBL] [Abstract][Full Text] [Related]
18. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
19. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
Komatani H; Morita M; Sakaizumi N; Fukasawa K; Yoshida E; Okura A; Yoshinari T; Nishimura S
Cancer Res; 1999 Jun; 59(11):2701-8. PubMed ID: 10363995
[TBL] [Abstract][Full Text] [Related]
20. Effects of topoisomerase I inhibition on the expression of topoisomerase II alpha measured with fluorescence image cytometry.
Nicklee T; Crump M; Hedley DW
Cytometry; 1996 Nov; 25(3):205-10. PubMed ID: 8914817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
